<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634580</url>
  </required_header>
  <id_info>
    <org_study_id>20140234</org_study_id>
    <nct_id>NCT02634580</nct_id>
  </id_info>
  <brief_title>Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4</brief_title>
  <acronym>GAUSS-4</acronym>
  <official_title>A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Japanese Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Data Monitoring Committee (DMC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis is that evolocumab (AMG 145) SC will be well tolerated and will result
      in greater reduction of LDL-C than ezetimibe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening subjects who meet all inclusion/exclusion criteria will be randomized with an
      allocation ratio of 2:2:1:1 into 4 groups: evolocumab (AMG 145) 420 mg administered by
      subcutaneous injection monthly and placebo pill daily; evolocumab (AMG 145) 140 mg
      administered by subcutaneous injection every two weeks and placebo pill by mouth daily;
      placebo 420 mg administered by subcutaneous injection monthly and ezetimibe 10 mg pill daily;
      placebo 140 mg administered subcutaneous injection every two weeks and ezetimibe 10 mg pill
      daily. Randomization will be stratified by screening LDL-C level and baseline statin use.
      Randomization should occur within 5 - 10 days of the screening LDL-C evaluation used to
      determine eligibility. Subjects on low or atypical statin dose therapy must be on a stable
      dose for at least 4 weeks prior to screening and throughout the blinded portion of the study;
      the dose cannot be adjusted during screening and for the duration of the study. After Week
      12, ezetimibe will be discontinued and subjects will move to an open label dose of evolocumab
      administered by subcutaneous injection either every two weeks or monthly and their standard
      of care.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2016</start_date>
  <completion_date type="Anticipated">May 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline in low density lipoprotein-cholesterol (LDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in low density lipoprotein-cholesterol (LDL-C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in low density lipoprotein-cholesterol (LDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean change from baseline in low density lipoprotein-cholesterol (LDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol (LDL-C)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from baseline in low density lipoprotein-cholesterol (LDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean low density lipoprotein-cholesterol response (LDL-C &lt; 70 mg/dL [1.8 mol/L])</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean low density lipoprotein-cholesterol response (LDL-C &lt; 70 mg/dL [1.8 mol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol response (LDL-C &lt; 70 mg/dL [1.8 mmol/L])</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Low density lipoprotein-cholesterol response (LDL-C &lt; 70 mg/dL [1.8 mmol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in total cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in non-high density lipoprotein-cholesterol (HDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in non-high density lipoprotein-cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-HDL-C</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in non-high density lipoprotein-cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B (ApoB)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in apolipoprotein B (ApoB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B (ApoB)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in apolipoprotein B (ApoB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in the total cholesterol/high density lipoprotein- cholesterol (HDL-C) ratio</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in the total cholesterol/high density lipoprotein- cholesterol (HDL-C) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in the total cholesterol/high density lipoprotein- cholesterol (HDL-C) ratio</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in the total cholesterol/high density lipoprotein- cholesterol (HDL-C) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in lipoprotein a [Lp(a)]</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in lipoprotein a [Lp(a)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipoprotein a [Lp(a)]</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in lipoprotein a [Lp(a)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in triglycerides</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in triglycerides</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in high density lipoprotein-cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in very low density lipoprotein-cholesterol (VLDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <description>Mean percent change from baseline in very low density lipoprotein-cholesterol (VLDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in very low density lipoprotein-cholesterol (VLDL-C)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent change from baseline in very low density lipoprotein-cholesterol (VLDL-C)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Arm1 - Evolocumab SC + Ezetimibe Placebo Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Evolocumab (AMG145) subcutaneous (SC) injection monthly and Ezetimibe matching placebo pill daily by mouth. At screening, all subjects will enter a placebo run-in period to confirm tolerance of subcutaneous administration prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Ezetimibe Pill + Evolocumab SC Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Ezetimibe pill daily by mouth and Evolocumab matching placebo subcutaneous injection monthly. At screening, all subjects will enter a placebo run-in period to confirm tolerance of subcutaneous administration prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Evolocumab SC + Ezetimibe Placebo Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Evolocumab (AMG 145) subcutaneous injection every two weeks and a Ezetimibe matching placebo pill daily by mouth. At screening, all subjects will enter a placebo run-in period to confirm tolerance of subcutaneous administration prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - Ezetimibe Pill + Evolocumab SC Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Ezetimibe pill daily by mouth and Evolocumab matching placebo subcutaneous injection every two weeks. At screening, all subjects will enter a placebo run-in period to confirm tolerance of subcutaneous administration prior to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Subjects will receive Evolocumab (AMG 145) subcutaneous monthly and Ezetimibe matching placebo pill daily by mouth.</description>
    <arm_group_label>Arm1 - Evolocumab SC + Ezetimibe Placebo Pill</arm_group_label>
    <other_name>Evolocumab (AMG 145)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Subjects will receive Ezetimibe pill daily by mouth and Evolocumab matching placebo subcutaneous monthly.</description>
    <arm_group_label>Arm 2 - Ezetimibe Pill + Evolocumab SC Placebo</arm_group_label>
    <other_name>Zetia (ezetimibe)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Subjects will receive Evolocumab (AMG 145) subcutaneous every two weeks and Ezetimibe matching placebo pill daily by mouth.</description>
    <arm_group_label>Arm 3 - Evolocumab SC + Ezetimibe Placebo Pill</arm_group_label>
    <other_name>Evolocumab (AMG 145)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Subjects will receive Evolocumab (AMG 145) every two weeks and Ezetimibe matching placebo pill daily by mouth.</description>
    <arm_group_label>Arm 4 - Ezetimibe Pill + Evolocumab SC Placebo</arm_group_label>
    <other_name>Zetia (ezetimibe)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 20 to ≤ 80 years of age

          -  Japanese by self-identification

          -  Not on a statin or on a low dose statin with stable dose for at least 4 weeks.

          -  Subject not at LDL-C goal

          -  History of statin intolerance to at least 2 statins

          -  Lipid lowering therapy has been stable prior to screening for at least 4 weeks

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  NYHA III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes

          -  Poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kisarazu-shi</city>
        <state>Chiba</state>
        <zip>292-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-shi</city>
        <state>Chiba</state>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chikushino-shi</city>
        <state>Fukuoka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <state>Fukuoka</state>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sukagawa-shi</city>
        <state>Fukushima</state>
        <zip>962-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sukagawa-shi</city>
        <state>Fukushima</state>
        <zip>962-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <state>Ibaraki</state>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komatsu-shi</city>
        <state>Ishikawa</state>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-0866</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ohsaki-shi</city>
        <state>Miyagi</state>
        <zip>989-6143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nakagami-gun</city>
        <state>Okinawa</state>
        <zip>901-2393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-Shi</city>
        <state>Osaka</state>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujimi-shi</city>
        <state>Saitama</state>
        <zip>354-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawaguchi-shi</city>
        <state>Saitama</state>
        <zip>332-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>430-0929</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashiyamato-shi</city>
        <state>Tokyo</state>
        <zip>207-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Musashino-shi</city>
        <state>Tokyo</state>
        <zip>180-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese</keyword>
  <keyword>High cholesterol</keyword>
  <keyword>Treatment of high cholesterol</keyword>
  <keyword>Lowering cholesterol</keyword>
  <keyword>Lowering high cholesterol</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Statin intolerant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

